Obesity management: update on orlistat.
Article Details
- CitationCopy to clipboard
Drew BS, Dixon AF, Dixon JB
Obesity management: update on orlistat.
Vasc Health Risk Manag. 2007;3(6):817-21.
- PubMed ID
- 18200802 [ View in PubMed]
- Abstract
Over the past 20 years obesity has become a worldwide concern of frightening proportion. The World Health Organization estimates that there are over 400 million obese and over 1.6 billion overweight adults, a figure which is projected to almost double by 2015. This is not a disease restricted to adults - at least 20 million children under the age of 5 years were overweight in 2005 (WHO 2006). Overweight and obesity lead to serious health consequences including coronary artery disease, stroke, type-2 diabetes, heart failure, dyslipidemia, hypertension, reproductive and gastrointestinal cancers, gallstones, fatty liver disease, osteoarthritis and sleep apnea (Padwal et al 2003). Modest weight loss in the obese of between 5% and 10% of bodyweight is associated with improvements in cardiovascular risk profiles and reduced incidence of type 2 diabetes (Goldstein 1992; Avenell et al 2004; Padwal and Majumdar 2007). Orlistat, a gastric and pancreatic lipase inhibitor that reduces dietary fat absorption by approximately 30%, has been approved for use for around ten years (Zhi et al 1994; Hauptman 2000). There is now a growing body of evidence to suggest that Orlistat assists weight loss and that it may also have additional benefits. The aim of this review is to provide a brief update on the current literature studying the efficacy, safety and significance of the use of Orlistat in clinical practice.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Orlistat Pancreatic triacylglycerol lipase Protein Humans YesInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareAlitretinoinOrlistat Orlistat can cause a decrease in the absorption of Alitretinoin resulting in a reduced serum concentration and potentially a decrease in efficacy. alpha-Tocopherol acetateOrlistat Orlistat can cause a decrease in the absorption of alpha-Tocopherol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. alpha-Tocopherol succinateOrlistat Orlistat can cause a decrease in the absorption of alpha-Tocopherol succinate resulting in a reduced serum concentration and potentially a decrease in efficacy. Beta caroteneOrlistat Orlistat can cause a decrease in the absorption of Beta carotene resulting in a reduced serum concentration and potentially a decrease in efficacy. D-alpha-Tocopherol acetateOrlistat Orlistat can cause a decrease in the absorption of D-alpha-Tocopherol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.